Pharmaceutical deals have the attention of competition regulators globally. After years of relative stability and predictability, clearances processes for pharmaceutical deals have become more uncertain. Skadden attorneys Justine Haimi, Yi (Julia) Zhu, Marta Navarro Hernandez and Weiran (Rachel) Yang discuss new theories of harm and remedies in pharmaceutical mergers in the EU, U.S. and APAC regions.
Recent Developments in the Analysis of Life Sciences Mergers
Competition Policy International